EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy

Navid Roessler iD, Zuzanna Nowicka iD, Marcin Miszczyk iD, Giorgio Calleris iD, Alessandro Dematteis iD, Malte W Vetterlein iD, Simone Albisinni iD, Henk G Van Der Poel, Paul Cathcart, Giovanni E Cacciamani iD, Inderbir S Gill iD, Raj A Persad iD und 11 weitere

BJU International · 2026-09 · 138 (3) · 430-437

DOI: 10.1111/bju.70352 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 15.06.2026. Verfasst von Navid Roessler und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy, Salvage Therapy. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 patients with recurrent, non‐metastatic, hormone‐sensitive prostate cancer treated with sRP at 13 centres. ICE surrogacy was evaluated using a two‐stage approach: (i) at the individual‐patient level by fitting Clayton copula models and estimating Kendall's ( >0.7 indicating a strong association) and (ii) at the centre level, by fitting weighted linear regression of 5‐year OS on 3‐year BRFS and MFS.

Results

The two‐step analysis included 759 patients for BRFS (366 events) and 476 for MFS (137 events), with median follow‐up of 37 months (95% confidence interval [CI] 36–42 months) and 34 months (95% CI 31–37 months), respectively. At the individual‐patient level, MFS showed a strong association with OS (Kendall's 0.85, 95% CI 0.82–0.88), which was not observed for BRFS (Kendall's 0.63, 95% CI 0.56–0.69). At the centre level, neither 3‐year BRFS ( R 2 = 0.15; slope = 0.34, P = 0.2) nor 3‐year MFS ( R 2 = 0.21; slope = 0.26, P = 0.14) predicted 5‐year OS with sufficient explanatory power. Limitations include the fact that centre‐level analysis was based on single‐arm associations rather than on treatment‐effect surrogacy across arms, and retrospective data collection.

Conclusions

The BRFS should not be used as a surrogate endpoint in the sRP setting. MFS requires further validation in future prospective studies to confirm its association with OS. Patient‐reported outcomes, such as quality‐of‐life and treatment‐related toxicity, should be considered in parallel with OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomySalvage TherapyHumansMaleRetrospective StudiesAgedMiddle AgedDisease-Free SurvivalProstate-Specific AntigenNeoplasm Recurrence, Local

Stichwörter der Autor:innen

biochemical recurrence‐free survivalintermediate clinical endpointmetastasis‐free survivalsalvage radical prostatectomysurrogate endpoints

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland.
  • Collegium Medicum, Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland.
  • Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany.

ORCID-Profile: Navid Roessler, Zuzanna Nowicka, Marcin Miszczyk, Giorgio Calleris, Alessandro Dematteis, Malte W Vetterlein, Simone Albisinni, Giovanni E Cacciamani, Inderbir S Gill, Raj A Persad, Steven Joniau, Rafael Sanchez-Salas, Joseph A Smith, Robert Jeffrey Karnes, Pawel Rajwa, Derya Tilki, Paolo Gontero, Giancarlo Marra

Zitieren

APA

Roessler, N., Nowicka, Z., Miszczyk, M., Calleris, G., Dematteis, A., Vetterlein, M. W., Albisinni, S., Van Der Poel, H. G., Cathcart, P., Cacciamani, G. E., Gill, I. S., Persad, R. A., Joniau, S., Sanchez-Salas, R., Smith, J. A., Karnes, R. J., Ahmed, M. E., Rajwa, P., Tilki, D., …, & Young Academic Urologists Prostate Cancer Working Party (2026). Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy. BJU International, 138(3), 430-437. https://doi.org/10.1111/bju.70352

Vancouver

Roessler N, Nowicka Z, Miszczyk M, Calleris G, Dematteis A, Vetterlein MW, et al. Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy. BJU International. 2026;138(3):430-437. doi:10.1111/bju.70352

BibTeX
@article{Roessler2026,
  author = {Roessler, Navid and Nowicka, Zuzanna and Miszczyk, Marcin and Calleris, Giorgio and Dematteis, Alessandro and Vetterlein, Malte W and Albisinni, Simone and Van Der Poel, Henk G and Cathcart, Paul and Cacciamani, Giovanni E and Gill, Inderbir S and Persad, Raj A and Joniau, Steven and Sanchez-Salas, Rafael and Smith, Joseph A and Karnes, Robert Jeffrey and Ahmed, Mohamed E and Rajwa, Pawel and Tilki, Derya and Shariat, Shahrokh F and Gontero, Paolo and Marra, Giancarlo and Young Academic Urologists Prostate Cancer Working Party, Young Academic Urologists Prostate Cancer Working Party},
  title = {Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {3},
  pages = {430--437},
  doi = {10.1111/bju.70352}
}
Kostenlos starten →